
Lidocaine, Vasoconstriction and the Safe Limits of Numbing Cream
A complete technical reference for body art professionals on the pharmacology of topical anesthetics used in tattooing and piercing, covering local anaesthetic mechanisms (sodium channel blockade), dermal absorption and systemic toxicity risks (LAST), vasoconstriction effects on healing and ink dispersal, safe application limits, and the varying legal status of numbing creams across the EU, USA, and ASEAN jurisdictions.
Topical anaesthetics are among the most widely used, least understood, and most dangerously misapplied pharmaceutical products in body art. A client applies a numbing cream purchased online, the artist tattoos for three hours, and the cream wears off at 90 minutes with the client in more pain than if they had started without it. Worse, some clients apply excessive amounts to large body surface areas under occlusion (plastic wrap), unknowingly creating the conditions for systemic local anaesthetic toxicity, a medical emergency that begins with perioral numbness and metallic taste and can progress to seizures and cardiac arrest before the artist realises anything is wrong.
This pillar covers the pharmacology of how these drugs work at the molecular level (sodium channel blockade), how they move through skin and into systemic circulation (dermal absorption kinetics), the clinical ceiling at which they become toxic (LAST risk thresholds), the contradictory effect of vasoconstrictors on healing and ink retention, and the fragmented regulatory landscape that leaves many artists operating in a legal grey zone between client demand and unlicensed medical practice.
How They Work: Sodium Channel Blockade and the pKa Problem
All local anaesthetics in clinical use share a common mechanism: reversible blockade of voltage-gated sodium channels (Nav1.x) on the intracellular side of the neuronal membrane [13]. The drug must first penetrate the axonal membrane in its uncharged (free base) form, then re-equilibrate to the charged (protonated) form inside the cell to bind the channel pore from the cytoplasmic side. This pH-dependent equilibrium is governed by the drug's pKa relative to the local tissue pH.
- »Lidocaine (pKa 7.9): At physiological pH 7.4, approximately 25% of lidocaine molecules are in the uncharged membrane-permeable form and 75% are protonated and trapped. In inflamed or infected tissue (pH 5.5-6.5), only about 0.4-4% is uncharged, rendering lidocaine nearly inactive. This is why anaesthetising inflamed tissue is clinically difficult, the drug cannot cross the membrane.
- »Prilocaine (pKa 7.9): Similar pH behaviour to lidocaine. The distinguishing feature is prilocaine's o-toluidine metabolite, which accumulates with high doses (>600 mg) and oxidises haemoglobin from Fe²⁺ to Fe³⁺, producing methemoglobinemia [15]. SpO₂ readings drop while PaO₂ (blood gas) remains normal, a diagnostic clue that the problem is haemoglobin dysfunction, not lung pathology.
- »Tetracaine (pKa 8.5): More potent than lidocaine (ester-type, not amide-type) with a higher pKa meaning less is uncharged at pH 7.4 (about 7%) [13]. The trade-off: slower onset but longer duration. Tetracaine is metabolised by plasma pseudocholinesterase, not hepatic CYP450, giving it a different toxicity profile from the amide local anaesthetics.
- »Eutectic Mixture (EMLA): The term "eutectic" describes a mixture of lidocaine and prilocaine in a specific ratio (1:1 by weight) where the melting point of the mixture is lower than either component alone [15]. This allows both drugs to exist as a liquid oil at room and skin temperature despite their individual melting points (lidocaine 68°C, prilocaine 37°C). The liquid-oil phase penetrates the stratum corneum far more effectively than crystalline solids. This is how EMLA reaches useful dermal concentrations with only 2.5% of each drug.
- »Lidocaine/Tetracaine 7%/7% Peel: A more recent formulation that dries into a peelable film [9]. Each drug is at 7%, against EMLA's 2.5%. It has been tested head to head against EMLA in randomised laser trials, including tattoo removal [6], but the higher concentration demands stricter surface-area limits.
Dermal Absorption: Why Surface Area Matters More Than Concentration
The systemic absorption of a topical anaesthetic is governed by Fick's Law: flux = permeability coefficient × concentration gradient × surface area / barrier thickness [10]. The skin barrier, the stratum corneum, is the rate-limiting step. Once a drug penetrates the stratum corneum, absorption into the dermal capillary plexus is rapid and near-complete. The single most dangerous variable the artist controls is not the concentration of the cream but the total surface area to which it is applied.
- »Surface Area Rule: Doubling the application area doubles systemic absorption at the same concentration. Halving the concentration but doubling the area results in the same systemic dose. An adult back is roughly 3,000 cm²: covering it at the label rate of 1.5-2 g per 10 cm² would take 450-600 g of EMLA, about 11-15 g of lidocaine, more than 35 times the 300 mg cap.
- »Occlusion Amplification: Plastic wrap hydrates the stratum corneum and traps heat, and both raise absorption. The two deaths in the FDA's 2007 advisory were young women who wrapped their legs in plastic after applying compounded lidocaine/tetracaine creams before laser hair removal [1].
- »Site Variability: Absorption varies by anatomical site. In the classic hydrocortisone study (Feldmann and Maibach, 1967), scalp skin absorbed about 3.5× and forehead about 6× the forearm rate, and the sole only about 0.14×. Mucosa (lips, genitals) has a much thinner barrier and absorbs far faster than any skin. A "standard" dose that is safe on the forearm can be toxic on the lip or perineum.
- »Broken Skin Multiplier: Abraded, razor-burned, freshly shaved, or recently lasered skin has effectively zero stratum corneum barrier. Absorption is near-injection equivalent. Pre-procedure skin preparation (shaving, exfoliation) significantly increases anaesthetic absorption and should be accounted for in dose calculations.
- »Vascularity and Clearance: Well-perfused skin carries absorbed drug into the circulation faster, so blood levels peak sooner and higher [11]. Less perfused skin releases it more slowly.
LAST: Local Anaesthetic Systemic Toxicity, the Ceiling Artists Must Know
Local anaesthetic systemic toxicity (LAST) is the clinical syndrome that results when plasma concentrations of local anaesthetic exceed the therapeutic range and begin affecting the central nervous system and myocardium [14]. The progression follows a predictable sequence: perioral numbness and metallic taste (from about 5 μg/mL), tinnitus and visual disturbances, muscle twitching and confusion, generalised tonic-clonic seizures, and finally cardiovascular collapse with bradycardia, hypotension, and asystole at the highest levels. Not every patient shows the early signs first. In the body art setting, LAST is largely preventable if the artist understands the dose-surface-area relationship before applying the cream.
- »CNS Toxicity (Early): GABA-ergic inhibitory interneurons are more sensitive to local anaesthetic blockade than excitatory glutamatergic neurons [13]. The initial effect is disinhibition, producing the classic prodrome of perioral numbness, metallic taste, lightheadedness, and tinnitus. These are WARNING SIGNS. If the client reports any of these during a session, remove the anaesthetic and monitor. Do not add more cream.
- »CNS Toxicity (Late): As plasma concentration rises, widespread cortical depression produces seizures, followed by coma and respiratory arrest. Seizure activity increases metabolic oxygen demand and produces lactic acidosis, which further destabilises cardiac conduction.
- »Cardiac Toxicity: Local anaesthetics block cardiac sodium channels (Nav1.5) with slower binding kinetics than neuronal channels, but the blockade accumulates and is use-dependent [13]. The result: prolonged PR interval, widened QRS complex, progressive bradycardia, and eventually asystole or pulseless electrical activity. Bupivacaine (rare in topical preparations) has the highest cardiotoxicity due to very slow dissociation from cardiac sodium channels. Lidocaine is less cardiotoxic but not zero-risk.
- »Lipid Rescue Therapy: Intravenous lipid emulsion (Intralipid 20%, 1.5 mL/kg bolus followed by 0.25 mL/kg/min infusion) is the specific antidote for LAST [14]. It works by creating an expanded plasma lipid phase that sequesters lipophilic local anaesthetic molecules, reducing free plasma concentration. The artist does not administer this, but knowing it exists means calling emergency services immediately with the specific diagnosis ("suspected lidocaine toxicity") rather than a generic "client is unwell".
- »Methemoglobinemia (Prilocaine Specific): Unlike lidocaine toxicity which is dose-dependent and predictable, methemoglobinemia from prilocaine's o-toluidine metabolite is idiosyncratic and can occur at standard doses in susceptible individuals [15]. Presentation: cyanosis with normal PaO₂, chocolate-brown blood, SpO₂ reading stuck at ~85% regardless of oxygen delivery. Specific treatment: methylene blue 1-2 mg/kg IV. Activated charcoal is not effective for already-absorbed drug.
Vasoconstriction: The Double-Edged Sword of Epinephrine
Standard creams for intact skin (EMLA, plain lidocaine creams) contain no vasoconstrictor. Epinephrine (adrenaline) is found in injectable lidocaine, at 1:100,000 (10 μg/mL) or 1:200,000 (5 μg/mL), and in some numbing gels sold for broken skin during tattooing. The rationale is sound: by constricting local capillaries, epinephrine reduces the rate at which the anaesthetic is washed out of the dermis, prolonging its effect and reducing systemic absorption. But vasoconstriction also reduces local tissue perfusion, and in the context of tattooing, this creates a conflict with the wound-healing process that depends on adequate blood flow.
- »Prolonged Anaesthesia: In injected lidocaine, epinephrine roughly doubles the duration by reducing clearance. For long tattoo sessions, this is mechanically advantageous but pharmacologically cumulative: the same 300 mg lidocaine dose now has a longer window to absorb through hypoperfused skin.
- »Ischaemic Risk: Vasoconstriction reduces tissue oxygen tension. In a freshly tattooed wound, the tissue oxygen demand is elevated (inflammation, cellular recruitment, debris clearance). Reducing perfusion during this critical window can theoretically delay healing, increase the risk of localised tissue necrosis in areas with already marginal blood supply (distal extremities, previously scarred skin, areas with subcutaneous fillers), and compromise the fibroblast function essential for pigment encapsulation.
- »Ink Dispersal Interference: The initial hours after tattooing are when macrophage recruitment and ink particle phagocytosis begin. Adequate perfusion delivers monocytes to the dermal pigment depot. Vasoconstriction during and immediately after the procedure may reduce the number of macrophages reaching the ink, potentially altering the pattern of pigment retention and contributing to uneven healing or premature fading.
- »Systemic Epinephrine Absorption: While the primary concern with topical anaesthetics is lidocaine toxicity, epinephrine is not benign at systemic doses. Absorption through large surface areas or broken skin can produce tachycardia, hypertension, anxiety, and tremors. Case reports document systemic epinephrine toxicity from epinephrine-containing topical anaesthetic gels [4], including on mucosal surfaces [5], where absorption is far higher than through intact skin.
- »Epinephrine-Free Alternatives: For clients with cardiovascular conditions, hypertension, or anxiety disorders, epinephrine-free formulations (plain lidocaine, lidocaine/prilocaine without vasoconstrictor) are the safer choice. The trade-off is shorter duration and higher systemic absorption of the anaesthetic itself, requiring stricter surface-area limits.
Safe Topical Anaesthetic Application Protocol
These steps convert the pharmacology into a repeatable, documented procedure that protects both the client and the studio. Every application should follow this sequence without exception.
- 1Pre-screening: Ask the client about known allergies to local anaesthetics (amide or ester types), current medications (fluvoxamine, cimetidine and propranolol all reduce lidocaine clearance), cardiovascular conditions, pregnancy, and G6PD deficiency (methemoglobinemia risk with prilocaine).
- 2Calculate the maximum safe dose: Body weight (kg) × 5 mg/kg (lidocaine) or 6 mg/kg (prilocaine) [13]. For a combination product like EMLA, use the lower cap. Record this number in the client record.
- 3Measure the treatment area: Estimate area in cm² (hand-sized area ≈ 150 cm²). As a studio rule, stay under 300 cm² for EMLA and 200 cm² for lidocaine/tetracaine 7%/7% in a single application.
- 4Check skin integrity: Do not apply to broken, abraded, razor-burned, or recently lasered skin absent explicit clinical rationale. Absorption through compromised barrier is near-injection equivalent.
- 5Apply the minimum effective amount: For EMLA, 1.5-2.0 g per 10 cm² is the clinical standard [15]. More cream does not mean more anaesthesia, it means more systemic absorption. Spread evenly, do not massage in.
- 6Occlude only if needed: If using occlusion (plastic wrap), document the start time and set a timer for exactly the manufacturer-recommended duration (typically 60-90 minutes). Do not exceed this. Do not occlude large areas (>200 cm²).
- 7Remove thoroughly: At the timer, remove all residual cream with a dry wipe, then wash the area with mild soap and water. Residual cream continues absorbing after removal unless washed off.
- 8Ask the toxicity screening questions: Before starting the procedure, ask: "Do you feel any numbness or tingling around your mouth? Any metallic taste? Any ringing in your ears?" A "yes" to any of these is a STOP signal. Do not proceed.
- 9Monitor during the procedure: Check in with the client every 30 minutes using the same three questions. Epinephrine-containing creams produce cardiac effects (palpitations, anxiety) that clients may attribute to "needle anxiety" but are pharmacological.
- 10Document everything: Product name, batch number, concentration, amount applied (g), surface area (cm²), occlusion time, client responses to screening questions, and any adverse effects. This record is the studio's legal defence if a reaction occurs.
- 11Post-procedure: Advise the client not to apply additional anaesthetic cream at home ("the session was long, I'll put more on to sleep") without consultation. Re-application within 12 hours compounds systemic dose.
- 12Emergency preparedness: Know the signs of LAST (perioral numbness, metallic taste, tinnitus → seizures → cardiac arrest) [14]. Have the local emergency number accessible. Inform emergency services of the specific drug (lidocaine, prilocaine, tetracaine), estimated dose, and time of application.

Common Errors and Failure Modes
These are the most frequent mistakes in topical anaesthetic use in body art, and the clinical consequences of each.
- Dosing by intuition instead of calculation — "Two tubes should be fine" is not a dose calculation. A 50 kg client receiving two 30 g tubes of EMLA (2.5% lidocaine = 750 mg per tube, total 1,500 mg) receives 30 mg/kg of lidocaine, six times the 5 mg/kg maximum. Applied dose is not absorbed dose, but a cap exceeded sixfold leaves no safety margin.
- Applying cream then immediately starting — Topical anaesthetics require 30-90 minutes for meaningful dermal penetration depending on formulation. Starting immediately means tattooing through unanaesthetised skin. The client experiences full pain, the cream is wasted, and residual drug continues absorbing throughout the session.
- Using unknown or unregulated products — Creams purchased online from unregulated sources may contain undisclosed concentrations, undeclared active ingredients (benzocaine, tetracaine at unknown %), or microbial contamination [1]. A product labelled "5% lidocaine" from an unlicensed manufacturer is an unknown-risk exposure.
- Occluding large areas for long sessions — A full back occluded for 120 minutes under plastic wrap creates near-maximum absorption conditions. The systemic dose from a whole back under occlusion can exceed the threshold for LAST even when the per-unit-area dose is "standard".
- Reapplication during a long session without dose tracking — A client whose EMLA wore off at 90 minutes into a 6-hour session receives a second application at hour 2. By hour 6, the cumulative dose is additive, not independent. The elimination half-life of lidocaine (~90 minutes) means plasma concentration builds across reapplication episodes.
- Ignoring drug interactions — Fluvoxamine (an SSRI) blocks CYP1A2, the main enzyme for lidocaine, and cut lidocaine clearance by about 60% in healthy volunteers [16]. Cimetidine inhibits hepatic metabolism and raises lidocaine levels [13]. Propranolol reduces liver blood flow and with it lidocaine clearance. A standard dose in a client on these medications is not a standard risk.
- Applying cream to mucosal surfaces — Lip, oral, genital, and anal mucosa absorb topical anaesthetics far faster than skin [5]. A dose calculated for forearm skin reaches the blood far faster when applied to the lip. Mucosal application requires separate, lower dosing guidelines and is inherently higher risk.
- Pregnancy and lactation assumptions — Lidocaine crosses the placenta and is excreted in breast milk. While lidocaine sat in the old FDA Pregnancy Category B (no risk shown in animal studies; the letter categories were retired in 2015), the combination of pregnancy-related increased cardiac output (faster systemic absorption) and altered plasma protein binding (lower albumin = higher free drug fraction) changes the pharmacokinetic profile. Prilocaine carries additional methemoglobinemia risk to the foetus, whose fetal haemoglobin is more susceptible to oxidation.
Regulatory Framework by Jurisdiction
Topical anaesthetics exist at the intersection of pharmaceutical regulation and cosmetic practice, creating a legal grey zone in many jurisdictions. Some classify numbing creams as prescription-only medicines, others as over-the-counter products with concentration limits, and some lack specific regulation entirely. The professional standard should follow the most conservative interpretation: if the product alters physiology (sodium channel blockade, vasoconstriction), it is a drug, and its use in a commercial body art setting requires a documented risk assessment regardless of local legal classification.
- Classification is national, not set by the EMA. In the UK, EMLA (2.5%/2.5%) is a pharmacy (P) medicine, sold under a pharmacist's supervision.
- Cosmetics Regulation (EC) 1223/2009: Products making anaesthetic claims are not cosmetics and fall under medicinal product regulation.
- MHRA (UK): Topical anaesthetics used for non-medical purposes (tattooing) are in a regulatory grey area. Under MHRA borderline guidance, a product that works by a pharmacological action is a medicine by function, whatever it is marketed as.
- Product licensing: EMLA cream holds a Marketing Authorisation (MA) as a medicinal product. Unlicensed imports or compounded preparations used in studios violate medicines legislation.
- Professional indemnity: check whether your insurer covers topical anaesthetic use, and on what conditions, before offering it.
- Ireland HPRA: Similar framework to MHRA. Topical anaesthetics for tattooing not explicitly regulated but medicinal product law applies.
- FDA OTC Monograph: Lidocaine up to 4% and benzocaine up to 20% are permitted in OTC topical anaesthetic products. Concentrations above this are prescription-only or unapproved drugs.
- FDA public health advisories (2007, 2009): after two deaths linked to compounded numbing creams used under plastic wrap, the FDA warned against application to large areas, wrapping, and use on broken or irritated skin [1].
- Compounded preparations: Many "numbing creams" marketed to tattoo studios are compounded products not subject to FDA pre-market approval. Their concentration, sterility, and ingredient accuracy are unverified.
- State-level rules: in Oregon, a 2026 Health Licensing Office practice clarification says administering topical anaesthesia is outside a tattoo artist's scope of practice; a client applying their own is not regulated by the Board [2]. Other states vary: check your state board.
- DEA scheduling: Lidocaine, prilocaine, and tetracaine are not controlled substances. Epinephrine is not scheduled. This creates a permissive distribution environment that contrasts with the pharmacological risk.
- Liability: Studios are advised to maintain product sourcing records and application documentation as legal protection.
- Thailand: topical lidocaine products are medicines under the Drug Act; check the Thai FDA (อย.) classification of the specific product. Tattoo studios using numbing creams without medical supervision operate in an enforcement gap.
- Singapore HSA: EMLA cream is registered as a Pharmacy Only medicine and lidocaine/tetracaine cream (Pliaglis) as Prescription Only. Importing or selling unregistered numbing creams breaches the Health Products Act.
- Malaysia NPRA: numbing creams are medicines that must be registered with the NPRA; check each product's registration and sale category. Enforcement in tattoo settings is minimal but the legal framework exists.
- Australia TGA: topical lidocaine up to 10% of total local anaesthetic is Schedule 2 (Pharmacy Medicine), stronger preparations are Schedule 4 (Prescription Only), and dermal preparations of 2% or less are exempt. In NSW, tattooists may not supply Schedule 2 products.
- New Zealand Medsafe: check the current classification of each product; studio use without pharmacist supply documentation is a compliance risk.
- Regional practice: In Thailand, Vietnam, and Indonesia, unregulated numbing creams are widely available in tattoo supply channels. The absence of enforcement does not eliminate the pharmacological risk, the drug does not know it is unregulated.
Patrick's Note
"I have seen the same numbing cream tube in studios across Bangkok, London, and Los Angeles, and the conversation is always the same: the artist trusts it because it says '5% lidocaine' on the label. The percentage on the tube tells you nothing about the dose your client is receiving. The dose is concentration × amount × surface area, and the surface area is the variable no one calculates. When I designed the [Medication Interaction Checker](/medication-interaction-checker/), it was specifically to catch the drug-drug interactions (SSRIs, beta-blockers, cimetidine) that turn a standard topical dose into an unpredictable plasma level. My rule for our own studio: if the client needs more than 10 g of any numbing product for a single session, we split the session across two days. Pain management in body art should be about client comfort, not pharmacological brinkmanship."
Founder & Piercing Expert
Poli International
Common Questions
▸What does this technical reference cover and why is it essential for working professional tattooists and piercers?
▸What key safety numbers and toxicity thresholds must an artist know to ensure client safety?
▸What is the correct sequence of steps for carrying out the anesthetic procedure?
▸What are the specific dangers of dosing by intuition and how can an artist avoid this error?
▸What are the risks associated with occluding large body surface areas and how can these risks be mitigated?
▸What do current regulations require for topical anesthetic products across different global regions?
Anatomical Plates
Free Body Art Wall Posters
Print-ready reference posters for your studio or your own wall. Free to download and display, embed on your own site with attribution. Click any poster to preview it full size before downloading.
Page map · Pharmacology, Topical Anesthetics in Tattooing
- Pharmacology, Topical Anesthetics in Tattooing
- Critical Numbers
- Conservative Cap on Applied Lidocaine
- Conservative Cap on Applied Prilocaine
- How They Work
- Lidocaine (pKa 7.9)
- Prilocaine (pKa 7.9)
- Dermal Absorption
- Surface Area Rule
- Occlusion Amplification
- LAST
- CNS Toxicity (Early)
- CNS Toxicity (Late)
- Vasoconstriction
- Prolonged Anaesthesia
- Ischaemic Risk
- Safe Topical Anaesthetic Application Protocol
- Pre-screening
- Calculate the maximum safe dose
- Common Errors and Failure Modes
- Dosing by intuition instead of calculation
- Applying cream then immediately starting
- Regulatory Framework by Jurisdiction
- European Union & UK
- United States
- Patrick's Note
- Related Topics
- Needle Geometry and Physics
- Skin Optics and Pigment Appearance
Built from this page's own sections, so it always matches what is below. It is a map of the page, not a set of claims, and carries no citations of its own.
Technical Specifications
| Parameter | Standard / Value |
|---|---|
| Conservative Cap, Applied Lidocaine | 5 mg/kg (intact skin); ~300 mg for 60 kg adult |
| Conservative Cap, Applied Prilocaine | 6 mg/kg; ~360 mg for 60 kg adult |
| Lidocaine Plasma Toxicity (CNS) | >5 μg/mL (perioral numbness, metallic taste, tinnitus) |
| Lidocaine Plasma Toxicity (Cardiac) | Roughly 10-20 μg/mL and above (seizures, arrhythmia, collapse) |
| Lidocaine pKa | 7.9 (~25% uncharged at pH 7.4) |
| EMLA Onset | 60-90 minutes under occlusion |
| EMLA Duration | ~2 hours after removal |
| Lidocaine/Tetracaine 7%/7% Onset | 30 minutes (peel formulation) |
| Dermal Absorption Rate Range | A few % on intact skin (EMLA: ~3-6%); far more on broken skin or mucosa |
| Mucosal Absorption | Far faster than intact skin |
| Methemoglobinemia Risk (Prilocaine) | o-toluidine metabolite, threshold >600 mg total dose |
| Lipid Rescue Therapy | Intralipid 20%, 1.5 mL/kg bolus then 0.25 mL/kg/min infusion |
| Lidocaine Elimination Half-Life | ~90 minutes (hepatic CYP3A4/CYP1A2) |
| Epinephrine in Numbing Products | Injectables and some broken-skin gels; not in EMLA |
| FDA OTC Lidocaine Limit | 4% (above this is prescription or unapproved) |
Revision Deck
15 cards, taken directly from this page's specifications. Nothing here is generated: the deck is the same reviewed data as the table above. See the full table.
Printable wall chart (A4) — the critical numbers, the do-nots and the applicable standards on one page for the bench.
References
- [1]FDA Public Health Advisory, topical anesthetics for cosmetic procedures (2007; 2009 update)https://webarchive.library.unt.edu/web/20090116195207/http:/www.fda.gov/cder/drug/advisory/topical_anesthetics2009.htm
- [2]Oregon Health Authority, EBAP practice clarification: administration of topical anesthesia (2026)https://www.oregon.gov/oha/PH/HLO/Documents/EBAP-Practice_Clarification-Administration_of_Topical%20Anesthesia-05-20-2026.pdf
- [3]American Society of Anesthesiologists (ASA), Standards and Practice Parametershttps://www.asahq.org/standards-and-practice-parameters
- [4]Fateha MJ et al., Epinephrine-Containing Topical Anesthetic Gel Inducing Systemic Epinephrine Toxicity (Cureus, 2023)https://pubmed.ncbi.nlm.nih.gov/37809235/
- [5]Elmezayen ZW et al., Systemic Epinephrine Toxicity Following Topical Anesthetic Gel on Mucosal Surfaces (Clin Med Insights Case Rep, 2026)https://pubmed.ncbi.nlm.nih.gov/42051598/
- [6]Greveling K et al., Comparison of lidocaine/tetracaine cream and lidocaine/prilocaine cream for local anaesthesia during laser treatment of acne keloidalis nuchae and tattoo removal (Br J Dermatol, 2017)https://pubmed.ncbi.nlm.nih.gov/27377616/
- [7]Cohen JL et al., Pain management with a topical lidocaine and tetracaine 7%/7% cream with laser dermatologic procedures (J Drugs Dermatol, 2013)https://pubmed.ncbi.nlm.nih.gov/24002144/
- [8]Keating SC et al., Evaluation of EMLA cream for preventing pain during tattooing of rabbits (PLoS One, 2012)https://pubmed.ncbi.nlm.nih.gov/22970216/
- [9]Chen JZ et al., Evaluation of the S-Caine Peel for induction of local anesthesia for laser-assisted tattoo removal (Dermatol Surg, 2005)https://pubmed.ncbi.nlm.nih.gov/15841627/
- [10]Hoppel M et al., Assessment of Drug Delivery Kinetics to Epidermal Targets In Vivo (AAPS J, 2021)https://pubmed.ncbi.nlm.nih.gov/33782803/
- [11]Cross SE et al., Effect of perfusion flow rate on the tissue uptake of solutes after dermal application (J Pharm Pharmacol, 1994)https://pubmed.ncbi.nlm.nih.gov/7699574/
- [12]Singh P et al., Effects of vasoconstriction on dermal pharmacokinetics and local tissue distribution of compounds (J Pharm Sci, 1994)https://pubmed.ncbi.nlm.nih.gov/9120806/
- [13]Becker DE et al., Local Anesthetics: Review of Pharmacological Considerations (Anesth Prog, 2012)https://pubmed.ncbi.nlm.nih.gov/22822998/
- [14]Neal JM et al., The Third ASRA Practice Advisory on Local Anesthetic Systemic Toxicity: Executive Summary 2017 (Reg Anesth Pain Med, 2018)https://pubmed.ncbi.nlm.nih.gov/29356773/
- [15]European Medicines Agency, EMLA (lidocaine/prilocaine) Summary of Product Characteristicshttps://www.medicines.org.uk/emc/search?q=EMLA
- [16]Orlando R et al., Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function (Clin Pharmacol Ther, 2004)https://pubmed.ncbi.nlm.nih.gov/14749694/
Put Science Into Practice
This technical standard is the architectural foundation for our professional analytical tools.
